Direct activation of NLRP3 by K + efflux
The stimulatory effect that cytosolic K + depletion has on IL-1β proteolytic processing and secretion from LPS-primed macrophages and monocytes, in response to compounds such as ATP or nigericin, was observed long before the discovery of inflammasomes [1] [2] [3] . This effect is now known to be mediated by NLRP3 4 , and K + efflux remains the best-characterized minimal stimulus for NLRP3 inflammasome activation 5 . Conversely, incubation in media containing supraphysiological [K + ] can block NLRP3 inflammasome assembly in response to most of the identified NLRP3 triggers 5 .
The major classes of NLRP3 activators include extracellular ATP at millimolar concentrations, K + ionophores 4 and crystalline/ particulate substances, or other factors that cause lysosomal destabilization 6, 7 . All of these stimuli are known to decrease the cytosolic level of K + ions 5 , but the mechanisms of K + efflux induction (summarized in Figure 1 ) differ for all classes of NLRP3 triggers. Before discussing these mechanisms in detail, it is important to reiterate some of the basic features of cellular K + homeostasis. ] e ; ~5 mM), and this distribution is approximately reversed for Na + ions. This asymmetry is maintained by the Na + /K + -ATPase, an electrogenic ion pump transporting, during each cycle, two K + cations into the cytosol and three Na + cations into the extracellular milieu. Secondly, under basal conditions, the permeability of most mammalian plasma membranes is highest with respect to the K + cations and much lower for Na + and Ca
2+
. Together, these factors contribute to sustaining the transmembrane potential of mammalian cells, which is characterized by a slight excess of negative charge on the inside of the cell. Each cycle of the Na + /K + -ATPase produces an electric charge difference of one elementary unit, and slow leakage of K + ions from the cell is not counterbalanced by a compensatory influx of another type of cation 8 . Plasma membranes in basal states can generally be regarded as electrical insulators 9 , so translocations of even small numbers of individual ions (much too small to cause any measurable changes in the intracellular concentration of the respective ion) produce significant changes in the value of transmembrane potential 8 . Similarly, transporting ions in the direction opposite to the electrical gradient (i.e. cations to the outside of the cell or anions into the cell) requires significant energy input. In this light, the dramatic decrease in [K + ] i required for NLRP3 activation, estimated as a drop of at least ~20-30% 5 , can be expected to be accompanied by either a counter-flux of cations or a "co-flux" of anions, which should also be provided by NLRP3 stimuli. While the proposed mechanism explains how MSU crystal-induced lysosomal damage can activate the NLRP3 inflammasome, it cannot account for NLRP3 activation with stimuli such as silica or cholesterol crystals because these particles do not dissociate in the lysosomal pH and are consequently not expected to influence cellular osmolarity. Investigating the kinetics and molecular mechanism of K + loss in cells undergoing lysosomal damage may prove highly relevant for understanding how the different NLRP3 stimuli trigger inflammasome assembly and for designing treatments that specifically target NLRP3 activation by crystalline agents, which underlies multiple inflammatory diseases. [18] [19] [20] . In response to NLRP3 activators, NEK7 is recruited to NLRP3 upstream of inflammasome formation (in a manner independent of ASC and caspases-1/11). NEK7 can also be detected in NLRP3/ASC specks, and formation of high-molecular-weight NLRP3 complexes that occurs upstream of ASC specking requires that NEK7 interacts with NLRP3. The NLRP3-NEK7 interaction is dependent on K . Interestingly, the catalytic activity of NEK7 is required neither for its binding to NLRP3, nor for the activation of the NLRP3 inflammasome 18, 20 .
The requirement for NEK7 in NLRP3 activation restricts this process to cells in interphase. At the endogenous level of NEK7, NLRP3 activators are able to enhance the interaction between NLRP3 and NEK7 in LPS-primed interphase cells but not in cells that have entered mitotic division, and LPS-primed interphase cells show a significantly higher level of caspase-1 activation than do their mitotic counterparts. Of note, NEK7 overexpression partially restores the responses to NLRP3 stimuli in mitotic cells, suggesting that the endogenous amount of NEK7 is not sufficient to simultaneously participate in both cell division and NLRP3 activation 20 .
It remains unknown how NEK7 is recruited to NLRP3 in response to a decrease in [K + ] i and whether elevating the interaction between NLRP3 and NEK7 above a certain threshold is sufficient to trigger the NLRP3 inflammasome assembly. In partial response to the first question, it was found that stimulation with ATP increases NEK7 phosphorylation 20 . This increase could be blocked with N-acetylcysteine, a scavenger of reactive oxygen species (ROS) that also potently inhibits IL-1β release upon stimulation with ATP 5,20,21 . However, it has not been clearly demonstrated that the enhanced phosphorylation of NEK7 is required for its interaction with NLRP3 and for NLRP3 inflammasome activation. Furthermore, shRNA-mediated silencing of NEK9, a kinase that interacts with NEK7 and causes its activation 22 , does not inhibit NLRP3 activation 18 , suggesting either that NEK7 activation is not required for the NLRP3 inflammasome assembly or that the ROS-dependent NEK7 activation occurs through an as-yet-unidentified mechanism. Further elucidation of this discrepancy and of the detailed mechanism by which NEK7 contributes to NLRP3 activation will be the next important step towards understanding the molecular mechanism of inflammasome assembly.
Differential requirements for K + efflux and NEK7 presence in autoinflammatory disease-related NLRP3 mutants Several single amino acid substitutions in NLRP3 are causative for systemic inflammation observed in a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS; cryopyrin being a synonym of NLRP3): neonatal onset multisystem inflammatory disease (NOMID), Muckle-Wells syndrome (MWS), and familial cold autoinflammatory syndrome (FCAS) 23 . Of these, mainly the MWS-associated mutant NLRP3 R260W (whose mouse counterpart is Nlrp3
R258W
) has been studied with respect to the requirement for K + efflux for inflammasome assembly. Interestingly, activation of the Nlrp3 R258W mutant occurs in macrophages expressing Nlrp3 R258W in response to extracellular LPS stimulation (independent of any classical triggering stimuli) and without the requirement for K + efflux 5 . However, NEK7 deficiency dramatically reduces the ability of Nlrp3
-expressing macrophages to activate the inflammasome in response to extracellular LPS
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. NLRP3
G775A and NLRP3 G775R mutants, which are mainly associated with NOMID, show a stronger association with NEK7 than does WT-NLRP3 when overexpressed in HEK293 cells and, conversely, the inflammasome activation-incompetent NLRP3 D946G mutant associates with NEK7 less strongly 20 . Collectively, these observations suggest that some of the CAPS-causative mutations in NLRP3 could promote inflammasome activation by facilitating the interaction between NLRP3 and NEK7, but such a conclusion requires further elucidation of the mechanism by which NEK7 is involved in the activation of different NLRP3 variants.
Non-canonical NLRP3 activation by caspase-11 involves K + efflux Murine caspase-11 and its human orthologues caspases-4 and -5 are cytosolic LPS sensors 24 that, upon recognition of their ligand, trigger non-canonical inflammasome activation 25 . This process consists of pyroptotic cell death that is independent of the canonical NLRP3 inflammasome components 26 and NLRP3-, ASC-, and caspase-1-dependent IL-1β/IL-18 processing and secretion 25 . Recent studies demonstrated that NLRP3 activation downstream of caspase-11 is mediated by K + efflux 27, 28 . This process is initiated by caspase-11-mediated cleavage of pannexin-1 26 , a plasma membrane-resident channel permeable to molecules and ions with a molecular weight of up to ~1 kDa 29 . Two molecular events follow the proteolytic processing of pannexin-1: (a) K + efflux (a direct NLRP3 stimulus that induces mIL-1β secretion) and (b) release of ATP, which in turn acts as an agonist of P2X7R to promote cell death 26 . Surprisingly, the levels of ATP released from cells upon caspase-11 activation and proposed to activate P2X7R are much lower (nanomolar concentrations) than the amounts of ATP typically required to activate this receptor when added as an exogenous stimulus 30 . The mechanism by which intracellular LPS recognition increases macrophage sensitivity to extracellular ATP is not yet identified.
Another effector mechanism of caspase-11 activation involves proteolytic cleavage of a cytosolic protein, gasdermin D [31] [32] [33] . The signaling pathways activated upon cleavage of gasdermin D are unknown, but it was demonstrated that, while overexpression of full-length gasdermin D, or of gasdermin D C-terminal fragment, does not cause any apparent changes in cell physiology, expression of gasdermin D N-terminal fragment alone is highly cytotoxic 32 . This observation evinces that the N-terminal fragment of gasdermin D is one of the downstream effectors of caspase-11. Important questions to be answered in further investigation of the role of gasdermin D in non-canonical inflammasome activation are whether overexpression of the gasdermin D N-terminal fragment is sufficient to activate the NLRP3 inflammasome and whether this process involves K + efflux. As gasdermin D N-terminal fragment alone is sufficient to cause pyroptosis, which is associated with plasma membrane disruption, it could be envisaged that this also leads to K + depletion.
Similar to pannexin-1 26 , gasdermin D is required for both cell death and IL-1β release in response to intracellular LPS 32, 33 . While IL-1β secretion observed under conditions of intracellular LPS stimulation is dependent on NLRP3, pyroptosis elicited by intracellular LPS only depends on pannexin-1 26 and gasdermin D 32,33 and is unaffected in NLRP3-deficient cells. The recent discoveries on the caspase-11 effector mechanisms leading to non-canonical inflammasome activation and to pyroptosis are summarized in Figure 2 . Future studies should address the questions of whether-and howthe caspase-11-mediated events (pannexin-1 and gasdermin D Figure 2 . Noncanonical NLRP3 activation by cytosolic LPS. Upon recognition of LPS in the cytosol, caspase-11 cleaves pannexin-1 and gasdermin D. Cleavage of pannexin-1 leads to opening of the channel and leakage of K + and ATP from the cell into the extracellular space. This efflux of K + ions activates the NLRP3 inflammasome, causing proteolytic processing and secretion of IL-1β. Simultaneously, ATP acts as an agonist for the P2X7R, leading to NLRP3 inflammasome-independent pyroptotic cell death. Proteolytic cleavage of gasdermin D produces a highly toxic N-terminal fragment of this protein, which mediates both activation of the NLRP3 inflammasome (with subsequent IL-1β processing and secretion) and NLRP3-independent pyroptotic cell death. The relationship between two caspase-11 effectors, pannexin-1 and gasdermin D, is currently not understood.
proteolytic processing) converge to orchestrate pyroptotic cell death. In particular, the mechanism by which gasdermin D N-terminal fragment induces cytotoxicity will have to be resolved, and the potential role of pannexin-1 cleavage in this process will have to be investigated more closely. Furthermore, there is a proposed mechanism by which the caspase-11/pannexin-1/NLRP3 axis triggers IL-1β/IL-18 secretion 26 , but it remains unknown how gasdermin D is involved in this process.
Adding to our knowledge on canonical inflammasome activation, active caspase-1, alongside caspase-11, was also demonstrated to cleave gasdermin D
32
. In response to activators of various canonical inflammasomes, gasdermin D-deficient macrophages exhibit delayed kinetics of cell death 32 and decreased levels of secreted IL-1β [31] [32] [33] , which suggests that caspase-1-catalysed proteolysis of gasdermin D is one of the effector mechanisms of pyroptosis and that it may contribute to non-classical cytokine secretion.
Mechanisms of NLRP3 activation independent of K + efflux Recently, it was reported that inhibition of glycolysis by targeting enzymes that catalyze two of the late reactions of this pathway, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or α-enolase, is sufficient to elicit inflammasome activation in an NLRP3-dependent manner 34 . The proposed sequence of events consists of a decrease in cellular [NADH]/[NAD + ] ratio, and a consequent increase in the levels of mitochondrial ROS, which, it is suggested, are involved in NLRP3 activation 35, 36 . Interestingly, supplementation with the glycolytic metabolite pyruvate (which is normally produced downstream of the inhibited steps of glycolytic cascade) or with succinate (one of the TCA cycle metabolites; both pyruvate and succinate can enhance TCA cycle activity) leads to a decrease in the level of both generated mitochondrial ROS and NLRP3 inflammasome activation 34 . Such an observation suggests that in this pathway mitochondrial ROS act as NLRP3 stimuli. This mechanism of NLRP3 activation is uncommon because it does not require K + efflux: inhibition of GAPDH and α-enolase can trigger assembly of the NLRP3 inflammasome at supraphysiological Another mechanism of NLRP3 activation independent of K + efflux is observed in monocytes but is restricted to several species (e.g. humans or pigs) and not observed in murine cells. For this mechanism of NLRP3 activation, termed "alternative inflammasome activation", extracellular LPS is a stimulus sufficient to elicit mature IL-1β release but not to cause ASC speck formation or pyroptosis. LPS acts as an agonist of TLR4, leading to engagement of the adaptor protein TRIF and of the RIPK1-FADD-caspase-8 signaling cascade, culminating in caspase-1 activation in an NLRP3-and ASC-dependent manner 39 . The specific nature of the signaling events that drive alternative NLRP3 activation as well as the fact that this mechanism does not lead to the generation of ASC specks may collectively suggest an involvement of a distinct, K + efflux-independent active NLRP3 conformation in this process. ] gradient between the ER lumen and the cytosol) either inhibits 40 or does not influence 47 NLRP3 activation, demonstrating that translocation of Ca 2+ ions into the cytosol is not sufficient to trigger that process. Of note, thapsigargin was demonstrated to elicit modest IL-1β secretion from LPS-primed human macrophages, but it is not known whether the mature form of the cytokine is secreted and whether this process is mediated by NLRP3
Ca

48
. Furthermore, thapsigargin was demonstrated to cause NLRP3 activation by inducing ER stress, but the role of Ca 2+ in this process has not been studied 49 . . Surprisingly, one study reports that human macrophages can secrete IL-1β in response to ionomycin, a Ca 2+ ionophore, but, similar to the case of thapsigargin, the involvement of NLRP3 is not proven and it is not demonstrated that the released form of the cytokine is proteolytically processed 48 .
Interestingly, in the NLRP3 response to hypotonic environments, extracellular Ca 2+ influx through mechanosensitive TRP channels and consequent activation of the kinase TAK1 were both demonstrated to be required for activation of the inflammasome alongside RVD-mediated K + efflux
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. It is unknown whether this mechanism also contributes to inflammasome assembly by all NLRP3 stimuli, but it is suggested that TAK1 is involved in NLRP3 activation induced by lysosomal damage 51 . Finally, one study proposed that Ca 2+ influx into the cytosol follows K + efflux caused by NLRP3 stimuli and that this Ca 2+ flux promotes activation of the inflammasome by enhancing mitochondrial ROS generation 52 . However, there are two major limitations to this conclusion. First, the only method applied for targeting cytosolic Ca 2+ was cell loading with BAPTA-AM, which may exert numerous off-target effects 53 . Secondly, the only tested NLRP3 activator was ATP, a cation channel opener and inducer of PLC (through interaction with P2Y2 receptor 54 ), which makes it challenging to dissect the relative contributions of the various ion fluxes in the process of inflammasome activation.
The mitochondrial Ca 2+ stores are the most difficult to perturb experimentally, and consequently their potential role in NLRP3 activation is not well understood. Several reports suggest that an increased Ca 2+ uptake by the mitochondria may promote mitochondrial damage and NLRP3 responses 40, 55, 56 , although it was also demonstrated that mitochondrial damage inflicted by canonical NLRP3 activators is at least in part dependent on NLRP3 and caspase-1 57 . The transporter responsible for mitochondrial Ca 2+ uptake during NLRP3 activation by the membrane attack complex (a component of the complement cascade) and by Pseudomonas aeruginosa has been identified as mitochondrial Ca 2+ uniporter (MCU) 55, 56 . The specific factors that could tie an increase in mitochondrial [Ca 2+ ] to NLRP3 inflammasome assembly have not been identified, and it remains unknown whether MCU is involved in NLRP3 responses to its classical, better-characterized activators. 58 , reevaluation of the mechanisms by which application of BAPTA-AM or suppression of CaSR signaling interfere with NLRP3 activation could provide valuable insights into the molecular events that regulate NLRP3 inflammasome assembly. We further discuss some aspects of GPCR/CaSR signaling below.
Physiological and pharmacological modulation of NLRP3
The relevance of NLRP3 in human pathologies has led to research regarding both the intrinsic mechanisms that limit inflammasome activation and the possibility of pharmacological targeting of NLRP3. Even though such studies are challenging, because it is unclear how the K + efflux is transduced to NLRP3, they have nevertheless resulted in discoveries that processes such as cAMP signaling and autophagy can interfere with NLRP3 activation and in identification of several classes of exogenous small-molecule compounds that can act as specific inhibitors of NLRP3 activation. , although it is currently not clear whether this decrease occurs upstream or downstream of NLRP3 activation. One study suggested that inhibition of adenylyl cyclase enzymatic activity (surprisingly, using KH7, an inhibitor targeting the GPCRindependent soluble adenylyl cyclase and not acting on the GPCRregulated transmembrane adenylyl cyclases 61 ) might be sufficient to activate the NLRP3 inflammasome 42 , but this result could not be reproduced, possibly due to differences in the applied concentrations of the compound 60 . Of note, inhibitors of transmembrane adenylyl cyclases also do not act as NLRP3 inflammasome activators, pointing to a modulatory role of [cAMP] i rather than its decrease being the direct NLRP3 stimulus.
Inhibition of the NLRP3 inflammasome by cAMP
Pharmacological targeting of various cAMP-binding proteins that act as downstream effectors of adenylyl cyclase activation revealed that the inhibitory effect that cAMP exerts on NLRP3 activation cannot be ascribed to the currently known cAMP targets 42, 59, 60 . In the study that identified cAMP as a regulator of NLRP3, it was proposed that NLRP3 could form a complex with cAMP 42 , and recently it was demonstrated that the NLRP3-cAMP complex recruits ubiquitin ligase MARCH7, which in turn labels NLRP3 for degradation in autophagosomes , the inhibitor of soluble, GPCR-independent adenylyl cyclases 66 , to interfere with events that, it is proposed, occur downstream of GPCR-responsive transmembrane adenylyl cyclases. Applying genetic rather than pharmacological approaches to the studies on the influence of cAMP on NLRP3 activation and a more thorough investigation of the roles of established cAMPbinding proteins in this process could potentially provide a greater insight into the mechanism of NLRP3 response inhibition by cAMP.
Regulation of inflammasome responses by autophagy
Autophagy is emerging as a central process regulating multiple inflammasome responses at several levels. Pro-IL-1β can be degraded in autophagosomes, leading to decreased inflammatory responses to a range of stimuli 67 . In addition, it is also proposed that autophagy specifically controls NLRP3 activation over other characterized inflammasomes. Suppression of the autophagic processes impairs homeostatic turnover of mitochondria, promoting mitochondrial damage that contributes to caspase-1 activation in response to ATP 68 , as well as in the NLRP3 response to influenza A virus infection 69 . A decrease in the number of autophagosomes was also reported in response to palmitate, a long-chain fatty acid previously demonstrated to activate NLRP3 70 . However, activation of NLRP3 using nigericin or crystalline stimuli enhanced autophagy, 71 targeting inflammasome components for degradation in the autophagosomes. Collectively, these observations suggest that reduction in the autophagic processing of cellular contents may support NLRP3 inflammasome responses. Conversely, increased autophagy may act as a regulator of the NLRP3 inflammasome specifically and a regulator of IL-1β-based inflammation generally by a negative feedback loop. The recent discoveries that dopamine decreases cellular responses to NLRP3 activators by targeting this inflammasome sensor protein for degradation in autophagosomes 60 and that NF-κB signaling can inhibit activation of NLRP3 by stimulating the autophagic turnover of dysfunctional mitochondria 72 demonstrate that this regulatory mechanism can position immune cells towards a state of decreased sensitivity to NLRP3 stimuli even before they encounter inflammasome activators. The proposed mechanisms of regulation of NLRP3 responses by autophagy and by cAMP (discussed earlier) are summarized in Figure 3 .
Inhibition of the NLRP3 inflammasome by compounds containing a sulfonylurea moiety The first observation that compounds containing a sulfonylurea moiety potently inhibit ATP-or hypotonicity-induced IL-1β processing and release predates the discovery of inflammasomes 73 . This phenomenon was later recognized as specific inhibition of the NLRP3 inflammasome 74 , and until now virtually all validated NLRP3 activators are sensitive to sulfonylurea-containing compounds, such as glyburide or CP-456,773 75 . Sulfonylurea drugs seem to specifically inhibit the triggering step of NLRP3 activation without affecting the NF-κB signaling-related priming step or the activation of other inflammasomes 74, 75 . Compounds containing sulfonylurea moieties have been tested, as NLRP3 inhibitors, in several animal inflammatory disease models, usually with encouraging results [75] [76] [77] [78] [79] . Of note, alternative inflammasome activation (described in more detail above) can also be blocked by 773 39 .
The mechanism by which sulfonylurea compounds inhibit NLRP3 activation is currently not understood. Given that an important target of these pharmaceuticals are K + channels [80] [81] [82] and that K + efflux is required for NLRP3 activation 5 , one concept would be that sulfonylureas could impede K + efflux from cells treated with NLRP3 stimuli. However, not all sulfonylurea drugs can inhibit inflammasome activation 74 and, conversely, sulfonylurea compounds were demonstrated not to prevent K + efflux caused by NLRP3 activators 75 , which collectively suggests that these inhibitors act downstream of K + depletion and that the inhibition mechanism is not related to the activity of these compounds on K + channels. Glyburide was shown to inhibit the ATPase activity of NLRP3, but it is unclear whether other drugs from this class can act in a similar manner, and if this observation is related to the glyburidemediated inhibition of inflammasome formation. 773 (CRID3 83 , which has recently been renamed to MCC950 75 ) has been demonstrated not to affect the Ca 2+ flux in cells treated with ATP 75 , which, some studies suggest, plays a role in NLRP3 activation 40 . The influence of CP-456,773 on other molecular events connected to NLRP3 activation, such as the production of ROS, decrease in [cAMP] i , or recruitment of NEK7 to NLRP3, has not yet been tested.
Attempts to identify the molecular target of 773 showed that this compound interacts with proteins from the glutathione S-transferase family 83 , but so far none of these have been shown to transduce the information about K + efflux to the NLRP3 inflammasome. There is conflicting evidence regarding the ability of sulfonylurea drugs to inhibit the activation of CAPS-related NLRP3 mutants, as glyburide has been shown not to affect IL-1β release from cultured monocytes from an FCAS-affected patient 74 , but CP-456,773 suppressed mutant NLRP3 activation in both the cAMP is believed to bind to the nucleotide-binding domain of NLRP3. This formed NLRP3-cAMP complex recruits the ubiquitin ligase MARCH7 that polyubiquitinates NLRP3, targeting it for autophagosomal degradation. Autophagosomes are also the organelles responsible for degradation of pro-IL-1β (the inactive pro-form of the proinflammatory cytokine IL-1β), which is a more general mechanism controlling the inflammatory responses mediated by a range of inflammasomes. Finally, mitophagy is a way to dispose of damaged mitochondria that starts with sequestering them in autophagosomes. Autophagosomal degradation of dysfunctional mitochondria curbs the inflammasome responses, possibly by removing the source of direct NLRP3 activators. mouse model of MWS and in monocytes from an MWS-affected patient 75 . The NLRP3 mutants investigated in these studies had different amino acid substitutions, which, together with other differences in the experimental systems, could have led to this apparent discrepancy. A more comprehensive study addressing the sensitivity of a range of hyperactive NLRP3 mutants to sulfonylurea compounds could provide more insight into whether these drugs can inhibit inflammasome activation by these protein variants and what the mechanism of inhibition could be. 84, 85 . In biological systems, these compounds can covalently modify protein Cys residues that are not engaged in disulfide bond formation 86, 87 . This mechanism explains the inhibition of the NLRP3 inflammasome both by compounds that are generally regarded as NLRP3 inhibitors (e.g. parthenolide and BAY 11-7082) 85 and compounds whose ability to inhibit NLRP3 activation has been identified as an "off-target" effect (e.g. the Syk kinase inhibitor 3,4-methylenedioxy-β-nitrostyrene [MNS]) 84 . Importantly, the issue of specificity of the tested inflammasome inhibitors has also been addressed in the cited studies and, while MNS and BAY 11-7082 have been demonstrated to selectively inhibit NLRP3, parthenolide was also able to block other inflammasome responses 84, 85 . This observation is probably related to parthenolidemediated direct inhibition of caspase-1 85 (which contains a Cys residue that is essential for its catalytic activity and which can also be modified by Michael acceptors 87 ).
Inhibition
In further investigation of the mechanism of NLRP3 inhibition by Cys-modifying compounds, two consecutive structureactivity relationship studies demonstrated that Michael acceptors with very diverse chemical structures can interfere with NLRP3 activation (assessed by IL-1β release and pyroptotic LDH release) 88, 89 . Of note, these compounds are capable of inhibiting NLRP3 ATPase activity 88, 89 . Furthermore, several Michael acceptors moderately but significantly inhibit the activation of CAPS-related NLRP3 variants, but their potency on these NLRP3 mutants is lower compared to the inhibitory influence exerted on WT-NLRP3 89 .
When applying compounds that contain a Michael acceptor moiety to investigate the molecular mechanism of NLRP3 activation, several issues have to be considered. First, the downstream effector of NLRP3 is caspase-1, a Cys protease whose catalytic activity depends on an unmodified, free Cys residue. This implies that Michael acceptors, at high enough concentrations, may obscure various experimental readouts that rely on caspase-1 activity, such as assessing inflammasome speck formation using the caspase-1-targeting FLICA reagent, IL-1β/IL-18 release, or pyroptotic LDH release, even if the particular compounds-of-interest do not directly interfere with NLRP3 activation. Second, the ability of Michael acceptors to directly interact with NLRP3/modify Cys residues in NLRP3 84,89 only suggests, but does not prove, that the NLRP3-Cys modification constitutes the mechanism of inflammasome inhibition by these compounds. Further insights into the structural basis of NLRP3 activation and into the possible influence of Michael acceptors on that process are required to resolve this issue.
Conclusions and future directions
In recent years, a number of molecular players involved in NLRP3 activation have been identified. Most importantly, the direct interaction of NLRP3 with the kinase NEK7 has been described, and its importance for the assembly of the NLRP3 inflammasome has been demonstrated. Major progress has also been made in our understanding of how intracellular LPS triggers caspase-11, leading to proteolytic processing of pannexin-1 and gasdermin D, and to non-canonical NLRP3 inflammasome activation. Finally, the mechanism by which human monocytes activate NLRP3 in response to extracellular LPS as a single stimulus has been solved and shown to rely on TLR4/TRIF-mediated activation of the RIPK1-FADD-caspase-8 cascade. On the other hand, physiologically relevant mechanisms, such as autophagy and cAMP signaling, have been proposed to down-regulate the activation of NLRP3, demonstrating the physiological importance of limiting NLRP3 inflammasome responses.
However, there still remain unanswered questions about the molecular events that link cytosolic K + depletion to NLRP3-/ NEK7-dependent inflammasome formation. Furthermore, the discovery of the dual function of gasdermin D (as a downstream effector of caspase-11 required for non-canonical NLRP3 activation and a substrate of inflammatory caspases required for pyroptosis) calls for closer investigation of the mechanism of action of this protein. In light of the reported K + effluxindependent modes of NLRP3 triggering that include alternative NLRP3 inflammasome activation and NLRP3 inflammasome activation upon inhibition of glycolysis, the relative contributions of these pathways to inflammatory responses will have to be evaluated. Finally, the mechanisms by which compounds containing sulfonylurea or Michael acceptor moieties cause NLRP3 inhibition will have to be defined, which may open new possibilities for potential future therapeutic applications of these molecules.
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